Treatment with GSK343 at higher doses significantly decreased the presence of large and prominent cell nuclei, and dysplasia in tongue tissue compared to the OSCC group, reestablishing tissue architecture and counteracting tumor progression through EZH2 inhibition. This evidence concerns the gene EZH2 and neoplasm.